Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols

Participating Site through the Participating Site Principal Investigator shall use its best reasonable efforts to: Personally conduct and supervise the Study or Studies in accordance with the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Manuals of Operations for the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols; Ensure that all associates, colleagues and employees assisting in the Study or Studies are informed about and adhere to their obligations under the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols and MOOs, and this Participating Site Agreement;Follow all the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols’ reporting guidelines for documentation of adverse event reporting. Ensure all data and biological specimens provided to Michigan by Participating Site shall be collected pursuant to and in accordance with the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols, the Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry MOOs, and the informed consent form signed by the subjects participating in the Study(ies).